Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced that its Board
of Directors has appointed three experienced healthcare executives with
over 65 years collective industry experience to its Board of Directors,
Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced that its Board of Directors has appointed three experienced healthcare executives with over 65 years collective industry experience to its Board of Directors, effective immediately. Dr. Frank Armstrong and Dr. Nikin Patel have been appointed Directors of the Company, and Dr. Martyn Davies will serve as an Advisor to the Company’s Board. Drs. Davies and Patel are co-founders of Molecular Profiles Ltd. (“Molecular Profiles”). Steve Kasnet, Chairman of Columbia’s Board of Directors, said, “We are pleased to welcome Drs. Armstrong, Patel and Davies to our Board of Directors. We look forward to benefiting from the insight and vast industry experience these knowledgeable individuals will bring.” Dr. Frank Armstrong has over 20 years of experience in development and management at major pharmaceutical and leading biotechnology companies, spanning all aspects of the drug evaluation, development and commercialization processes. Dr. Armstrong led Medical Science and Innovation in R&D at Merck Serono and previously led Worldwide Product Development at Bayer AG and the Worldwide Medical Organization at Zeneca. He also served as CEO of Fulcrum Pharma plc and President and CEO of CuraGen Corp., among others. Dr. Armstrong holds an honours degree and MBChB in Biochemistry and Medicine 1 from the University of Edinburgh in Scotland. He was elected as a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) in 1994, and Fellow of Royal College of Physicians, Edinburgh (FRCPE) in 1993. He currently serves on the Boards of six healthcare companies: Summit plc (non-executive Chairman), Asceneuron SA (executive Chairman), Xceleron (Chairman), Actino Pharma, Entelos and CardioRentis (non-executive Director). Dr. Nikin Patel is the founding Chief Executive Officer of Molecular Profiles. Dr. Patel has over 15 years’ technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the Queen’s Award for Enterprise, won by Molecular Profiles both in 2007 and 2011 in the Innovation category.